Key result
Apixaban switch resolves LAA thrombus developed during low-dose dabigatran therapy in an AF patient.
Why the study?
Does switching to apixaban resolve left atrial appendage thrombus developed during low-dose dabigatran treatment in a patient with atrial fibrillation?
Case Report (n=1)
Does switching to apixaban resolve left atrial appendage thrombus developed during low-dose dabigatran treatment in a patient with atrial fibrillation?
Switching from low-dose dabigatran to apixaban may be an effective strategy for resolving left atrial appendage thrombus in patients with atrial fibrillation.
May support switching to apixaban for LAA thrombus on low-dose dabigatran in AF; hypothesis-generating case report leaving generalizability open.
We describe a case of atrial fibrillation in which an intracardiac thrombus that could not be prevented with "low-dose" dabigatran treatment was resolved by switching to apixaban treatment. Thrombolysis using direct oral anticoagulants (DOACs) could be a therapeutic option for patients with intracardiac thrombi, although the efficacies of different DOACs seem to differ and need further examination.
No takes yet. Share an insight, caveat, or question.
Koyama et al. (2017) conducted a case report in Atrial fibrillation with intracardiac thrombus (n=1). Apixaban vs. Low-dose dabigatran was evaluated on Resolution of intracardiac thrombus. Switching to apixaban resolved a left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment in a patient with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: